Biotech Stock Live Chat Recap: ASCO & Obesity

BOSTON ( TheStreet) -- Welcome to the May Biotech Stock Live Chat. The floor is yours.

I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.

My special guest today is Nathan Sadeghi-Nejad, a longtime friend and healthcare analyst/investor for the past 15 years. Nate has been writing a weekly column for TheStreet since February. He's one of the sharpest biotech investors I know so it's a thrill to have him on this live chat to help answer your questions.

The American Society of Clinical Oncology (ASCO) released thousands of cancer drug research abstracts last night in advance of its closely followed annual meeting in two weeks. This, of course, has investors buzzing about cancer drug stocks, so let's discuss Array Biopharma ( ARRY), Onyx Pharma ( ONXX), Seattle Genetics ( SGEN), Ariad Pharma ( ARIA) and Celldex Therapeutics ( CLDX), or any other ASCO-related stock that interests you.

If cancer isn't your thing, then how about more discussion of obesity drugs stocks Arena Pharmaceuticals ( ARNA) and Vivus ( VVUS), both of which are gearing up for FDA drug approval decisions in the next two months.

Or, we could talk about Vertex Pharmaceuticals ( VRTX) and its exciting cystic fibrosis drug franchise which helped boost the company's market cap by billions of dollars last week.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.